文献速递免疫规划传染病防控与疫情报告

武汉株多抗原SARS-CoV-2病毒样颗粒疫苗对JN.1变异株的交叉保护

Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant.
PubMed 文献 · Vaccine · 2026-08-20

研究开发基于武汉株、整合S/E/M/N四种抗原的病毒样颗粒疫苗,在小鼠中评估不同免疫途径的免疫原性,并在K18-hACE2小鼠模型中进行攻毒保护实验。疫苗诱导的系统性IgG和细胞免疫虽不能中和JN.1,但完全预防了武汉株和JN.1攻毒后的死亡并显著抑制病毒复制。

要点

  • 武汉株多抗原VLP疫苗诱导系统性IgG和肺/全身抗原特异性T细胞应答。
  • 鼻内加强选择性增强黏膜IgA应答。
  • 疫苗血清不能中和JN.1,但仍完全保护K18-hACE2小鼠免于JN.1攻毒死亡。

核心结论

  • 基于武汉株的多抗原VLP疫苗可对抗原性分化的JN.1变异株提供交叉保护,该保护不能仅由可检测的血清中和活性解释,提示需要整合体液、细胞和局部免疫机制。

研究设计与样本

  • 使用杆状病毒双表达系统构建含S、E、M、N蛋白的武汉株多抗原VLP疫苗。
  • 小鼠经肌内初免后,分别通过肌内或鼻内途径加强,评估体液、黏膜和细胞免疫应答。
  • 在高度易感的K18-hACE2小鼠模型中进行武汉株和JN.1变异株攻毒保护实验。

主要发现

  • 两种免疫方案均诱导强烈的系统性IgG应答,鼻内加强选择性增强黏膜IgA应答。
  • VLP免疫小鼠血清有效中和同源武汉株,但对JN.1变异株未检测到中和活性。
  • VLP免疫在肺部和全身诱导抗原特异性CD4+和CD8+ T细胞应答。
  • 在K18-hACE2小鼠中,VLP免疫完全预防武汉株和JN.1攻毒后的死亡,并显著抑制呼吸道组织中的病毒复制。
  • 组织病理学显示免疫小鼠间质性肺病变轻微,伴 organized perivascular lymphocytic infiltration,肺部细胞因子分析显示免疫应答模式因攻毒株和免疫状态而异。

临床怎么用

  • 多抗原VLP疫苗策略可能通过非中和机制提供对变异株的交叉保护,提示疫苗设计应整合体液、细胞和局部免疫。
  • 鼻内加强可增强黏膜免疫,或为呼吸道疫苗免疫途径提供参考。

局限性

  • 研究为小鼠模型,结果外推至人类需进一步验证。
  • 未能确定介导交叉保护的具体免疫机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve through mutations in the spike (S) protein, leading to antigenically divergent variants such as the Omicron sublineage JN.1 that markedly reduce vaccine-induced neutralizing antibody activity. These limitations highlight the need for vaccine strategies that can induce multilayered protective immunity rather than relying solely on S protein-targeted immunity. Here, we developed a Wuhan-lineage-based multi-antigen virus-like particle (VLP) vaccine incorporating S, envelope (E), membrane (M), and nucleocapsid (N) proteins using a baculovirus dual-expression system. Mice were primed intramuscularly and boosted via either the intramuscular or intranasal route, and humoral, mucosal, and cellular immune responses were evaluated. Both vaccination regimens induced robust systemic IgG responses, whereas mucosal IgA responses were selectively enhanced following intranasal boosting. Sera from VLP-immunized mice efficiently neutralized the homologous Wuhan-lineage strain but showed no detectable neutralizing activity against the JN.1 variant. Despite this, VLP immunization elicited antigen-specific CD4+ and CD8+ T cell responses in both pulmonary and systemic compartments. In a highly susceptible K18-hACE2 mouse model, VLP immunization completely prevented mortality following challenge with both the ancestral Wuhan-lineage strain and the JN.1 variant and markedly suppressed viral replication in respiratory tissues. Histopathological analysis further showed minimal interstitial lung lesions with organized perivascular lymphocytic infiltration in vaccinated mice, while pulmonary cytokine analysis revealed qualitatively distinct immune response patterns depending on the challenge strain and vaccination status. Our findings show that a Wuhan-lineage-based multi-antigen VLP vaccine can provide cross-protection against an antigenically divergent SARS-CoV-2 variant that is not fully explained by detectable serum neutralizing activity alone, suggesting the importance of integrated immune responses involving humoral, cellular, and local immune mechanisms.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim SJ, Kim HW, Son SE, et al. Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant. Vaccine. 2026. PMID: 42623712. doi:10.1016/j.vaccine.2026.129059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。